Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Myelodysplastic syndromes: therapy and outlook.

Lyons RM.

Am J Med. 2012 Jul;125(7 Suppl):S18-23. doi: 10.1016/j.amjmed.2012.04.018. Review.

PMID:
22735747
2.

Evolving treatment options of myelodysplastic syndromes.

Verbeek W, Ganser A.

Ann Hematol. 2001 Sep;80(9):499-509. Review.

PMID:
11669297
3.

Optimal sequencing of treatments for patients with myelodysplastic syndromes.

Itzykson R, Fenaux P.

Curr Opin Hematol. 2009 Mar;16(2):77-83. doi: 10.1097/MOH.0b013e3283257a74. Review.

PMID:
19468268
4.

Strategies for achieving transfusion independence in myelodysplastic syndromes.

Thomas ML.

Eur J Oncol Nurs. 2007 Apr;11(2):151-8. Epub 2006 Aug 28. Review.

PMID:
16935559
5.

An update on the treatment of myelodysplastic syndromes.

Kurtin SE, Demakos EP.

Clin J Oncol Nurs. 2010 Jun;14(3):E29-44. doi: 10.1188/10.CJON.E24-E39.

PMID:
20529786
6.

Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.

Garcia-Manero G.

Am J Hematol. 2015 Sep;90(9):831-41. doi: 10.1002/ajh.24102. Review.

PMID:
26294090
7.

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.

Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW.

J Clin Oncol. 2011 May 20;29(15):1987-96. doi: 10.1200/JCO.2010.30.9245. Epub 2011 Apr 11.

8.

Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.

Keating GM.

Drugs. 2009;69(17):2501-18. doi: 10.2165/11202840-000000000-00000. Review.

PMID:
19911860
9.

Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.

Pan F, Peng S, Fleurence R, Linnehan JE, Knopf K, Kim E.

Clin Ther. 2010 Dec;32(14):2444-56. doi: 10.1016/j.clinthera.2010.12.003.

PMID:
21353113
10.

Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.

Götze K, Platzbecker U, Giagounidis A, Haase D, Lübbert M, Aul C, Ganser A, Germing U, Hofmann WK.

Ann Hematol. 2010 Sep;89(9):841-50. doi: 10.1007/s00277-010-1015-0. Epub 2010 Jun 22. Review.

PMID:
20567826
11.

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.

Edlin R, Connock M, Tubeuf S, Round J, Fry-Smith A, Hyde C, Greenheld W.

Health Technol Assess. 2010 May;14 Suppl 1:69-74. doi: 10.3310/hta14Suppl1/10. Review.

12.

Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?

Steensma DP.

Best Pract Res Clin Haematol. 2012 Dec;25(4):443-51. doi: 10.1016/j.beha.2012.10.007. Epub 2012 Oct 25. Review.

PMID:
23200541
13.

Risk-based management of myelodysplastic syndrome.

Steensma DP, Tefferi A.

Oncology (Williston Park). 2007 Jan;21(1):43-54; discussion 57-8, 62. Review.

14.

Treatment of myelodysplastic syndromes in elderly patients.

Sanchez JF.

Adv Ther. 2011 Mar;28 Suppl 2:1-9. doi: 10.1007/s12325-011-0001-9. Epub 2011 Mar 9. Review.

PMID:
21431504
15.

Update on the pharmacotherapy for myelodysplastic syndromes.

Duong VH, Komrokji RS, List AF.

Expert Opin Pharmacother. 2014 Sep;15(13):1811-25. doi: 10.1517/14656566.2014.937705. Epub 2014 Jul 31. Review.

PMID:
25080144
16.

The role of decitabine in the treatment of myelodysplastic syndromes.

Atallah E, Kantarjian H, Garcia-Manero G.

Expert Opin Pharmacother. 2007 Jan;8(1):65-73. Review.

PMID:
17163808
17.

Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.

Keating GM.

Drugs. 2012 May 28;72(8):1111-36. doi: 10.2165/11209430-000000000-00000. Review. Erratum in: Drugs. 2012 Jul 30;72(11):1578.

PMID:
22571445
18.

Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.

Garcia-Manero G.

Am J Hematol. 2012 Jul;87(7):692-701. doi: 10.1002/ajh.23264. Review.

19.

Clinical roundtable monograph. Overall survival and maintenance of MDS patients.

Silverman LR.

Clin Adv Hematol Oncol. 2009 Jul;7(7):S3-5.

PMID:
19708287
20.

Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.

Garcia-Manero G.

Am J Hematol. 2014 Jan;89(1):97-108. doi: 10.1002/ajh.23642. Review.

Items per page

Supplemental Content

Write to the Help Desk